Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 29,083 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: dose level 1 Clear all

Conditions: Prostate Cancer
Interventions: Trabectedin; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Arthritis, Psoriatic
Interventions: JNJ-88545223, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 18
States / cities: Searcy, Arkansas • Huntington Beach, California • San Diego, California + 15 more

Conditions: Patients With Gastroparesis Who Have Failed Standard Therapy
Interventions: Domperidone; Drug
Lead sponsor: Ron Schey; Other
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Interventions: NOX66, EBRT; Drug · Radiation
Lead sponsor: Noxopharm Limited; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Beverly Hills, California • Houston, Texas

Conditions: Congenital Adrenal Hyperplasia
Interventions: Abiraterone acetate; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 2 Years to 9 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 4
States / cities: Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more

Conditions: Botulism
Interventions: XOMA 3AB, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Leukemia
Interventions: Immunotoxin therapy, CAT-8015 immunotoxin, Biological therapy; Drug · Procedure
Lead sponsor: Cambridge Antibody Technology; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 3
States / cities: Beverly Hills, California • Indianapolis, Indiana • Bethesda, Maryland

Conditions: OBESITY, HYPERTENSION, PURE AUTONOMIC FAILURE, SHY-DRAGER SYNDROME
Interventions: Trimethaphan, Pseudoephedrine; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Type 2 Diabetes
Interventions: Liraglutide, Metformin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 25 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Leukemia, Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions: Azacitidine, Entinostat; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 3
States / cities: Baltimore, Maryland • New York, New York

Conditions: Advanced Solid Tumor, Solid Tumor
Interventions: BGB-26808, Tislelizumab, Chemotherapy; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 337 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Duarte, California • Los Angeles, California • New Haven, Connecticut + 6 more

Conditions: ICD
Interventions: CT scan of the chest without contrast; Radiation
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Stroke With Hemiparesis
Interventions: Botulinum Toxin commonly known as BOTOX®, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Malignant Glioma, Glioblastoma Multiforme, GBM, Astrocytoma, Oligodendroglioma
Interventions: 131I-TM601; Drug
Lead sponsor: TransMolecular; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 4
States / cities: Chicago, Illinois • Baltimore, Maryland • Grand Rapids, Michigan + 1 more

Conditions: Prostate Cancer
Interventions: Placebo, Methylphenidate, Counseling Sessions, Sham Exercise, Standardized Exercise Intervention Program, Cognitive Behavioral Therapy (CBT); Other · Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gout Attack
Interventions: Etanercept, Triamcinolone Acetonide; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 85 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Neurofibromatosis 1, Plexiform Neurofibroma
Interventions: Selumetinib; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Year to 8 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 11 more

Conditions: Asthma
Interventions: QGE031, Omalizumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 22
States / cities: Fresno, California • Hawaiian Gardens, California • Riverside, California + 19 more

Conditions: CoronaVirus Disease-2019 (COVID-19)
Interventions: ABBV-47D11, Placebo for ABBV-47D11, ABBV-2B04, Placebo for ABBV-2B04; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Glendale, California • Cutler Bay, Florida • Miami, Florida + 8 more

Conditions: Pancreas Cancer
Interventions: Pemigatinib 4.5 MG; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Glioblastoma, Glioblastoma Multiforme
Interventions: Disulfiram, Copper gluconate, Temozolomide; Drug · Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pneumococcal Infection
Interventions: V116, Placebo, PCV15, PPSV23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 518 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 8
States / cities: Mesa, Arizona • Hialeah, Florida • West Palm Beach, Florida + 5 more

Conditions: Colorectal Cancer
Interventions: capecitabine, oxaliplatin, resection, radiation therapy, FOLFOX; Drug · Procedure · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 119
States / cities: Mobile, Alabama • Auburn, California • Cameron Park, California + 94 more

Conditions: Breast Cancer
Interventions: STA-9090; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Search by objective public record fields.

A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis

A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1

Phase 1 PK Study of XOMA 3AB

Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

The Autonomic Nervous System and Obesity

Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes

MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Reconstruction of 12-Lead Electrogram From Intracardiac Signals From Defibrillators During or After Implantation

Study of Botulinum Toxin and Recovery of Hand Function After Stroke

A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma

Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy

Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma

Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)

Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas

Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer

Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer